Evidence map›Paper›PMID 39082245›Full record

ReviewThe Journal of international medical research2024

Lipoprotein (a) and cerebrovascular disease.

Constantine E Kosmas, Maria D Bousvarou, Evangelia J Papakonstantinou, Eleni-Angeliki Zoumi, Loukianos S Rallidis

Abstract readReview
In one paragraph

Review in The Journal of international medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025
    Review
  5. Review
  6. Review
  7. Lipoprotein(a) as a Risk Factor for Recurrent Ischemic Stroke in Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Constantine E Kosmas2nd Department of Cardiology, National & Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0003-3926-0304
Maria D BousvarouSchool of Medicine, University of Crete, Heraklion, Greece.
Evangelia J PapakonstantinouGeneral Directorate of Public Health and Social Welfare, Attica Region, Athens, Greece.
Eleni-Angeliki ZoumiUniversity of Exeter Medical School, Exeter, Devon, United Kingdom.
Loukianos S Rallidis2nd Department of Cardiology, National & Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of lipoprotein (a) [Lp(a)] in cerebrovascular disease is a topic of importance. In this narrative review, pertinent studies have been leveraged to comprehensively examine this relationship from diverse perspectives.Lp(a) shares structural traits with low-density lipoprotein cholesterol. Lp(a) is synthesized by hepatocytes, and its plasma levels are genetically determined by the LPA gene, which produces apolipoprotein (a).Numerous epidemiological studies have confirmed the positive correlation between elevated serum Lp(a) levels and the occurrence or recurrence of cerebrovascular events, especially ischemic strokes, in adults. It should be noted that the correlation strength varies among studies and is marginal in Mendelian randomization studies.Regarding pediatric patients, screening is currently limited to those with a relevant medical history. Lp(a) seems to play a significant role in the pathogenesis of arterial ischemic stroke in children because environmental thrombotic and atherogenic factors are generally not present.Phase 3 trials of novel Lp(a) targeting agents, such as pelacarsen and olpasiran, are anticipated to demonstrate their efficacy in reducing the incidence of stroke. Given the richness of the literature, new guidelines regarding Lp(a) screening and management in targeted populations are warranted to provide more effective primary and secondary prevention.

Indexed as

Lipoprotein(a)Cerebrovascular DisordersHumansRisk FactorsLipoprotein(a)atherosclerotic cardiovascular diseasecerebrovascular diseaseischemic strokeLipoprotein (a)lipoprotein (a) lowering agentpediatric stroke

Identifiers

PMID39082245
PMCPMC11295242

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.